Tailoring Treatment of EGFR-Mutated NSCLC: Pharmacy Perspectives to Improve Patient Care

Join us for this interactive symposium where pharmacy and oncology experts Val R. Adams, PharmD, FCCP, BCOP; Edward S. Kim, MD, FACP; and Philip Schwieterman, PharmD, MHA, provide their perspectives on the role of EGFR-targeted therapies in the management of patients with advanced EGFR-mutated NSCLC, including insights into the latest first-line and second-line clinical data and how pharmacists can safely and effectively apply these new practice-changing data into care plans for their patients.

Held in conjunction with AMCP Nexus 2018.


6:00 PM - 6:30 PM: Dinner and Registration

6:30 PM - 6:40 PM: Welcome and Introduction

6:40 PM - 7:00 PM: Overview of EGFR-Mutated NSCLC and Pharmacology of EGFR TKIs – Val R. Adams, PharmD, FCCP, BCOP

7:00 PM - 7:25 PM: Selecting First-line and Second-line Therapy in the Setting of EGFR-Mutated NSCLC – Edward S. Kim, MD, FACP

7:25 PM - 7:45 PM: Improving Patient Outcomes and Providing Cost-Effective Care in EGFR-Mutated NSCLC Philip Schwieterman, PharmD, MHA

7:45 PM - 8:00 PM: Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Edward Kim, MD

Philip Schwieterman, PharmD

Director of Oncology and Pediatric Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

Goal Statement
The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with EGFR-mutated non-small-cell lung cancer.

Target Audience
This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding therapy, especially as it relates to EGFR T790M mutations
  • Compare current and emerging frontline treatment strategies for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
  • Discuss the roles of oncology and managed care pharmacists in optimizing the use of targeted therapy in advanced EGFR-mutated NSCLC, managing therapy-related toxicities, improving adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care


Pharmacist Continuing Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-084-H01-P

Type of Activity: Knowledge

Upon completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.